跳至主要内容
临床试验/NCT01165931
NCT01165931撤回2 期

A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease

Bayer0 个研究点开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
Bayer
主要终点
The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration

研究概览

简要总结

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients with coronary artery disease

排除标准

  • Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization

研究组 & 干预措施

Arm 1

Experimental

干预措施: Riociguat (BAY63-2521) (Drug)

结局指标

主要结局

The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration

时间窗: Within 5 min after completion of the intracoronary Riociguat infusion

次要结局

  • Adverse event collection(Until 30 days after study drug treatment)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

Coronary Vasomotor Response After Riociguat Exposure | 临床试验